OBJECTIVE: The aim of this study was to compare the efficacy of @entity1814 -based concurrent chemoradiotherapy (CCRT) with that of @entity900 -based CCRT in @entity1 with @entity5 . METHODS: The medical records of @entity1 with @entity5 who had undergone CCRT between 2003 and 2007 were retrospectively reviewed. Of these, 129 @entity1 were treated postoperatively with CCRT (n  =  52) or primary CCRT (n  =  77). A total of 29 @entity1 were treated with @entity1814 -based postoperative CCRT and 23 @entity1 were treated with @entity900 -based postoperative CCRT. A total of 28 @entity1 were treated with @entity1814 -based postoperative CCRT, and 49 @entity1 were treated with @entity900 -based postoperative CCRT. Progression-free survival (PFS) and @entity1349 ( @entity1349 ) were compared between the treatment groups. RESULTS: With postoperative CCRT, there were no significant differences in recurrence rate (P  =  1.0000), PFS (log-rank: P  =  0.8503), and @entity1349 (log-rank: P  =  0.8926) between the two treatment groups. With primary CCRT, there were no significant differences in PFS (log-rank: P  =  0.7845) and @entity1349 (log-rank: P  =  0.3659). The frequency of acute @entity137 was not significantly different between the @entity900 -based postoperative CCRT group and the @entity1814 -based postoperative CCRT group. CONCLUSIONS: @entity1814 -based postoperative CCRT is an effective and well-tolerated regimen for both early-stage and advanced-stage @entity5 @entity1 .

Clinical efficacy of XXXX -based concurrent chemoradiotherapy for uterine @entity5 : a Tohoku @entity5 Unit Study.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cervical cancer'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival'] @entity1814 :: ('MESH:C053989', 'Chemical') :: ['Nedaplatin', 'nedaplatin']
@entity1814 :: (MESH:C053989,Chemical) :: ['nedaplatin']
